Clinical Study on Additional Treatment of Hyperuricemia with Dotinurad

Clinical Study on Additional Treatment of Hyperuricemia with Dotinurad - Clinical Study on Additional Treatment of Hyperuricemia with Dotinurad

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054141

Enrollment

Registered

2024-04-13

Start date

2024-03-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperuricemic patients with uric acid level of 7.0 mg/dL or higher while taking febuxostat

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hyperuricemia with uric acid level of 7.0 or higher while taking febuxostat

Exclusion criteria

Exclusion criteria: Patients who were deemed not appropriate to participate in this study by doctor

Design outcomes

Primary

Measure	Time frame
uric acid	—

Secondary

Measure	Time frame
1) BUN, Cr, eGFR 2) Cystatin C 3) Oxidized LDL, high sensitivity CRP 4) Albuminuria 5) Side effects	—

Countries

Japan

Contacts

Public ContactMitsue Akiyama

Sekino Laboratory Department of Research

skn-np@sekino-hospital.com03-3986-5501

Outcome results